Publisher
Springer Science and Business Media LLC
Reference39 articles.
1. Sebaaly J, Covert K (2018) Enoxaparin dosing at extremes of weight: literature review and dosing recommendations. Ann Pharmacother 52:898–909. https://doi-org.gate.lib.buffalo.edu/10.1177/1060028018768449
2. Sanderink GJ, Le Liboux A, Jariwala N, Harding N, Ozoux ML, Shukla U, Montay G, Boutouyrie B, Miro A (2002) The pharmacokinetics and pharmacodynamics of enoxaparin in obese volunteers. Clin Pharmacol Ther 72:308–318. https://doi.org/10.1067/mcp.2002.127114
3. Package insert : https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020164s085lbl.pdf
4. World Health Organization (2023) Obesity and Overweight. https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight. Accessed 17 November 2023
5. Levine MN, Planes A, Hirsh J, Goodyear M, Vochelle N, Gent M (1989) The relationship between anti-factor xa level and clinical outcome in patients receiving enoxaparine low molecular weight heparin to prevent deep vein thrombosis after hip replacement. Thromb Haemost 62:940–944. https://doi.org/10.1055/s-0038-1651032
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献